Immunocorrecting therapy of chronic bacterial prostatitis
- 作者: Novikov AI1, Zaezzhalkin VV1, Kucherov VA1, Frolov SY.1, Novikov AI1, Zaezzhalkin VV1, Kucherov VA1, Frolov SY.1
-
隶属关系:
- 期: 编号 4 (2010)
- 页面: 44-48
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277781
- ID: 277781
如何引用文章
全文:
详细
A total of 55 patients aged 20-59 years with recurrent chronic bacterial prostatitis (RCBP) entered a trial of immunomodulator panavir. The study group consisted of 40 patients. They were given standard treatment and panavir. The control group (n = 15) matched by all the studied characteristics received standard treatment only. Blood count, bacteriological characteristics of prostatic secretion, immunological status, subjective parameters were studied. RCBP patients were diagnosed to have marked disorders of interferon status. The addition of panavir to standard treatment of RCBP patients significantly improved treatment results. Therefore, panavir is recommended as an adjuvant in combined RCBP treatment.
参考
- Ткачук В. Н. Хронический простатит. М.: Медицина для всех; 2006.
- Мазо Е. Б. Хронический инфекционный простатит. В кн.: Пленум правления Российского о-ва урологов: Материалы. М.; 2004. 267-289.
- Хаитов Р. М., Пинегин Б. В. Иммуномодуляторы и некоторые аспекты их клинического применения. Клин. мед. 1996; 8: 7-12.
补充文件
![](/img/style/loading.gif)